WO2012141844A3 - Methods predicting risk of an adverse clinical outcome - Google Patents

Methods predicting risk of an adverse clinical outcome Download PDF

Info

Publication number
WO2012141844A3
WO2012141844A3 PCT/US2012/029500 US2012029500W WO2012141844A3 WO 2012141844 A3 WO2012141844 A3 WO 2012141844A3 US 2012029500 W US2012029500 W US 2012029500W WO 2012141844 A3 WO2012141844 A3 WO 2012141844A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
clinical outcome
adverse clinical
predicting risk
methods
Prior art date
Application number
PCT/US2012/029500
Other languages
French (fr)
Other versions
WO2012141844A2 (en
Inventor
James V. Snider
Original Assignee
Critical Care Diagnostics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics, Inc. filed Critical Critical Care Diagnostics, Inc.
Priority to CN201280023965.1A priority Critical patent/CN103718046B/en
Priority to JP2013558218A priority patent/JP6215713B2/en
Priority to ES12771826T priority patent/ES2750126T3/en
Priority to EP19190278.2A priority patent/EP3605104B1/en
Priority to EP12771826.0A priority patent/EP2686689B1/en
Publication of WO2012141844A2 publication Critical patent/WO2012141844A2/en
Publication of WO2012141844A3 publication Critical patent/WO2012141844A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of ST2 in a biological sample from the subject and determining a level of galectin-3 in a biological sample from the subject. Kits are also provided that include an antibody that specifically binds to ST2 and an antibody that specifically binds to galectin-3.
PCT/US2012/029500 2011-03-17 2012-03-16 Methods predicting risk of an adverse clinical outcome WO2012141844A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN201280023965.1A CN103718046B (en) 2011-03-17 2012-03-16 The method predicting the risk of bad clinical effectiveness
JP2013558218A JP6215713B2 (en) 2011-03-17 2012-03-16 How to predict the risk of adverse clinical outcomes
ES12771826T ES2750126T3 (en) 2011-03-17 2012-03-16 Procedures for predicting the risk of an adverse clinical outcome
EP19190278.2A EP3605104B1 (en) 2011-03-17 2012-03-16 Methods predicting risk of an adverse clinical outcome
EP12771826.0A EP2686689B1 (en) 2011-03-17 2012-03-16 Methods predicting risk of an adverse clinical outcome

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161453782P 2011-03-17 2011-03-17
US61/453,782 2011-03-17

Publications (2)

Publication Number Publication Date
WO2012141844A2 WO2012141844A2 (en) 2012-10-18
WO2012141844A3 true WO2012141844A3 (en) 2013-03-21

Family

ID=47009907

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/029500 WO2012141844A2 (en) 2011-03-17 2012-03-16 Methods predicting risk of an adverse clinical outcome

Country Status (6)

Country Link
US (4) US8728742B2 (en)
EP (2) EP2686689B1 (en)
JP (2) JP6215713B2 (en)
CN (2) CN103718046B (en)
ES (2) ES2897419T3 (en)
WO (1) WO2012141844A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
HUE039881T2 (en) 2002-05-09 2019-02-28 Brigham & Womens Hospital Inc 1l1rl-1 as a cardiovascular disease marker
EP2241888B1 (en) 2006-04-24 2011-10-05 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
WO2007143295A2 (en) * 2006-04-27 2007-12-13 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
JP5377289B2 (en) 2006-05-01 2013-12-25 クリティカル ケア ダイアグノスティクス インコーポレイテッド Diagnostic method for cardiovascular disease
SI2019965T1 (en) * 2006-05-02 2015-10-30 Critical Care Diagnostics, Inc. Differential diagnosis between pulmonary and cardiovascular disease
PT2827152T (en) 2008-04-18 2016-09-13 Critical Care Diagnostics Inc Predicting risk of major adverse cardiac events
CN106620692B (en) 2010-04-09 2021-04-09 重症监护诊断股份有限公司 Soluble human ST-2 antibodies and assays
WO2012141844A2 (en) 2011-03-17 2012-10-18 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
WO2013012945A1 (en) 2011-07-18 2013-01-24 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
EP3434260A1 (en) 2012-05-18 2019-01-30 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of ventricular tachyarrhythmia event
SG10201704311VA (en) 2012-08-16 2017-07-28 Critical Care Diagnostics Inc Methods for predicting risk of developing hypertension
CN104737170A (en) 2012-08-21 2015-06-24 重症监护诊断股份有限公司 Multimarker risk stratification
WO2015018022A1 (en) * 2013-08-08 2015-02-12 华为技术有限公司 Signal transmission method, network-side device and user equipment
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US20210223264A1 (en) * 2016-04-25 2021-07-22 Siemens Healthcare Diagnostics Inc. Diagnostic method(s) for detecting and treating post-infarct myocardium remodeling and diffuse myocardial fibrosis
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
RU2677611C1 (en) * 2018-04-16 2019-01-17 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Method for predicting adverse cardiovascular events for a period of 12 months in patients with chronic heart failure with recurrence of angina after myocardial revascularization
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
CN116063520A (en) 2019-01-30 2023-05-05 真和制药有限公司 anti-GAL 3 antibodies and uses thereof
CN113425271B (en) * 2021-05-20 2024-02-06 上海小芃科技有限公司 Daytime operation discharge judgment method, device, equipment and storage medium

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020155513A1 (en) * 1999-04-13 2002-10-24 Hsu Daniel K. Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma
US20060257946A1 (en) * 2003-06-06 2006-11-16 Ciphergen Biosystems, Inc Serum biomarkers in ischaemic heart disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
ATE530180T1 (en) 1997-04-02 2011-11-15 Brigham & Womens Hospital METHOD FOR DETERMINING THE INDIVIDUAL RISK PROFILES OF ATHEROSCLEROTIC DISEASES
US6210976B1 (en) 1997-06-10 2001-04-03 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
GB9827348D0 (en) 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
WO2000035473A2 (en) 1998-12-18 2000-06-22 Scios Inc. Methods for detection and use of differentially expressed genes in disease states
WO2000073498A1 (en) 1999-06-02 2000-12-07 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
WO2001070817A1 (en) 2000-03-21 2001-09-27 Medical & Biological Laboratories Co., Ltd. Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
US20020115081A1 (en) 2000-08-22 2002-08-22 Lee Richard T. Diagnosis and treatment of cardiovascular conditions
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US20030004132A1 (en) 2001-06-22 2003-01-02 Yan Chang Method and material for treating immune diseases
WO2003022987A2 (en) 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6810284B1 (en) 2001-11-21 2004-10-26 Pacesetter, Inc. Implantable cardiac stimulation system and method for monitoring diastolic function
HUE039881T2 (en) 2002-05-09 2019-02-28 Brigham & Womens Hospital Inc 1l1rl-1 as a cardiovascular disease marker
AU2003299441A1 (en) 2002-12-19 2004-07-14 Centre National De La Recherche Scientifique - Cnrs Nf-hev compositions and methods of use
US20040133079A1 (en) 2003-01-02 2004-07-08 Mazar Scott Thomas System and method for predicting patient health within a patient management system
EP1522857A1 (en) 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
US20060257558A1 (en) 2003-10-31 2006-11-16 Hiroshi Nomura Plasma polymerization of atomically modified surfaces
JP5649263B2 (en) 2003-11-26 2015-01-07 セレラ コーポレーション Genetic polymorphisms associated with cardiovascular disorders and drug responses, methods for their detection and uses
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2005291899A (en) 2004-03-31 2005-10-20 Akira Matsumori Examination method of heart disease
EP1731910A1 (en) 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
EP2241888B1 (en) * 2006-04-24 2011-10-05 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
WO2007143295A2 (en) 2006-04-27 2007-12-13 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
JP5377289B2 (en) 2006-05-01 2013-12-25 クリティカル ケア ダイアグノスティクス インコーポレイテッド Diagnostic method for cardiovascular disease
SI2019965T1 (en) 2006-05-02 2015-10-30 Critical Care Diagnostics, Inc. Differential diagnosis between pulmonary and cardiovascular disease
US8147817B2 (en) 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
CA2720614A1 (en) * 2008-04-07 2009-10-15 Kalobios Pharmaceuticals, Inc. Neutralization of gm-csf for the treatment of heart failure
PT2827152T (en) 2008-04-18 2016-09-13 Critical Care Diagnostics Inc Predicting risk of major adverse cardiac events
JP2011528115A (en) * 2008-07-14 2011-11-10 エフ．ホフマン−ラ ロシュ アーゲー Multi-marker panel for diagnosis, monitoring and treatment selection of patients with heart failure
CN102257390B (en) * 2008-10-29 2015-04-01 Bg医药股份有限公司 Galectin-3 immunoassay
CN106620692B (en) 2010-04-09 2021-04-09 重症监护诊断股份有限公司 Soluble human ST-2 antibodies and assays
WO2012141844A2 (en) 2011-03-17 2012-10-18 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
WO2013012945A1 (en) 2011-07-18 2013-01-24 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
EP3434260A1 (en) 2012-05-18 2019-01-30 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of ventricular tachyarrhythmia event
SG10201704311VA (en) 2012-08-16 2017-07-28 Critical Care Diagnostics Inc Methods for predicting risk of developing hypertension
CN104737170A (en) 2012-08-21 2015-06-24 重症监护诊断股份有限公司 Multimarker risk stratification
WO2015106081A1 (en) 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
USD800332S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
USD800333S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020155513A1 (en) * 1999-04-13 2002-10-24 Hsu Daniel K. Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma
US20060257946A1 (en) * 2003-06-06 2006-11-16 Ciphergen Biosystems, Inc Serum biomarkers in ischaemic heart disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MASAHISA SHIMPO ET AL., JOURNAL OF THE AMERICAN HEART ASSOCIATION, vol. 109, no. 18, May 2004 (2004-05-01), pages 2186 - 2190, XP002523097 *
RAVI V.SHAH ET AL.: "Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure", EUROPEAN JOURNAL OF HEART FAILURE, vol. 12, 2010, pages 826 - 832, XP055125266 *

Also Published As

Publication number Publication date
US9239333B2 (en) 2016-01-19
US9823257B2 (en) 2017-11-21
JP2018021926A (en) 2018-02-08
US20140234875A1 (en) 2014-08-21
CN103718046B (en) 2016-10-12
US8728742B2 (en) 2014-05-20
WO2012141844A2 (en) 2012-10-18
CN106940375A (en) 2017-07-11
CN103718046A (en) 2014-04-09
EP2686689A2 (en) 2014-01-22
EP3605104B1 (en) 2021-09-15
US20120276551A1 (en) 2012-11-01
US10393756B2 (en) 2019-08-27
ES2897419T3 (en) 2022-03-01
EP2686689B1 (en) 2019-08-07
EP3605104A1 (en) 2020-02-05
CN106940375B (en) 2019-03-08
JP6215713B2 (en) 2017-10-18
ES2750126T3 (en) 2020-03-25
EP2686689A4 (en) 2014-09-03
US20180292415A1 (en) 2018-10-11
JP2014514536A (en) 2014-06-19
US20160299153A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
WO2012141844A3 (en) Methods predicting risk of an adverse clinical outcome
WO2019213282A8 (en) Biomarkers for evaluating car-t cells to predict clinical outcome
WO2013008102A3 (en) Methods and compositions for evaluating and/or treating chronic immune diseases
WO2012031008A3 (en) Cancer-related biological materials in microvesicles
EA201301180A1 (en) BCMA-BASED STRATIFICATION AND THERAPY OF PATIENTS SUFFERING WITH MULTIPLE MYELOMA
DK2885641T3 (en) PROCEDURES FOR PREDICTING THE RISK OF HYPERTENSION DEVELOPMENT
WO2012154944A3 (en) Methods of treating autophagy-associated disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits
WO2012054639A3 (en) Nmr systems and methods for the rapid detection of analytes
WO2014151006A3 (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
WO2012118750A3 (en) Biological markers and methods for predicting response to b-cell antagonists
WO2011154139A3 (en) Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
WO2013068373A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
WO2013066369A3 (en) Methods for detecting graft-versus-host disease
MX357429B (en) Predictors for cancer treatment.
MX2013011431A (en) Methods for predicting and improving the survival of gastric cancer patients.
EP2569635A4 (en) Methods for diagnosing and treating encephalitis or epilepsy
WO2014053996A3 (en) Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs
WO2011133036A3 (en) Means and methods for determining risk of cardiovascular disease
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
WO2012131092A3 (en) Method and kits for the prediction of response/nonresponse to the treatment with an anti-egfr antibody in patients with colorectal cancer of all uicc stages
WO2012101219A3 (en) Complex mirna sets as novel biomarkers for lung diseases
EP2732288A4 (en) Biological microchip for the estimation of immunoglobulin e and g levels in human blood, method of assay thereof, and reagent kit comprising same
WO2011130647A3 (en) Compositions and methods for characterizing a myopathy
WO2014023808A3 (en) Method for evaluating a cancer patient for propensity to respond to a therapy

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2012771826

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013558218

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE